Cogentix Medical — Proxy Contest (May 2016)
39 slides from Cogentix Medical's proxy contest presentation, May 5, 2016
Slide 1: Rebuttal to Mr. Pell's ISS Submission
NASDAQ: CGNTRebuttal to Mr. Pell’s ISS SubmissionMay 5, 2016
Slide 2: Operating Performance: Failure to Fulfill Merger-Related Promises
* Operating Performance Pell Statement“Failure to Fulfill Merger-Related Promises” FACT: At the time of the merger, the Company stated that we would grow revenue at a faster rate than either Uroplasty or Vision-Sciences would have grown on their own as stand-alone public companies. This growth, in c
Slide 3: Meeting Our Commitments: Total VSCI Revenue Growth
Meeting Our Commitments Total VSCI Revenue Growth Since The Merger = 9 months following merger (CY15 vs. CY14) _™ Same period one year prior (CY14 vs. CY13) 25% 22% 20% 15% 13% 10% 5% 0% Q2 Cogentix Medical
Slide 4: Meeting Our Commitments: U.S. VSCI Revenue Growth
Meeting Our Commitments U.S. VSCI Revenue Growth Since The Merger = 9 months following merger (CY15 vs. CY14) _™ Same period one year prior (CY14 vs. CY13) 50% 42% 40% 30% 20% 10% 0% (10%) (12%) (20%) Cogentix Medical
Slide 5: U.S. Urology Direct Revenue Increases 144%
Meeting Our Commitments 9 Month U.S. Urology Direct Revenue Increases 144% $5,000 $4,500 $4,000 $3,500 $3,000 $2,500 $2,000 $1,500 $1,000 $500 so Cogentix ™9 months following merger (CY15 vs. CY14) _m™ Same period one year prior (CY14 vs. CY13) {$n thousands) $4,385 $1,813 $1,799 Q2 Q3 a4 9 MTHS
Slide 6: U.S. Urgent PC Revenue Growth
Meeting Our Commitments 35% 30% 25% 20% 15% 10% 5% 0% + Cogentix U.S. Urgent PC Revenue Growth = 9 months following merger (CY15 vs. CY14) _m Same period one year prior (CY14 vs. CY13) 30%
Slide 7: Consolidated Revenue Growth More Than Doubled
Meeting Our Commitments Consolidated Revenue Growth More Than Doubled = 9 months following merger (CY15 vs. CY14) _ m Same period one year prior (CY14 vs. CY13) 20% 18% 18% 16% 1s 13.4% 12% 12% 10% 10% 8% 1% 6% 6% 6% 6.4% 4% 2% 0% + Q2 Q3 Q4 9 MTHS Cogentix
Slide 8: First-Ever Cash Operating Profit
Meeting Our Commitments $2.0 $0.0 ($2.0) ($4.0) ($6.0) ($8.0) ($10.0) ($12.0) First-Ever Cash Operating Profit em mtonsy $1.0 Ul 7) He9) ($9.1) cy13 cy14 cyis CY16 (expectes) Cogentix
Slide 9: Operating Performance: High Cash Burn Rate Claim
* Operating Performance Pell Statement The Company has a “high cash burn rate”, “deteriorating cash position”, “rising debt level” and “increasing interest expense”. FACT:The Company’s cash balance is increasing. The Company has no current cash burn rate. The Company’s debt level is not rising as th
Slide 10: Operating Performance: Cost Synergies
* Operating Performance Pell Statement“When will the cost synergies be realized?” FACT: The first-ever cash operating profit in the history of either company was achieved within nine months of the merger. The cost synergies committed to at the time of the merger were not only met but exceeded by the
Slide 11: Corporate Governance: Board Response to Proposals
* Corporate Governance Pell Statement “Cogentix responded to Mr. Pell’s positions” after he “delivered the notice of nominations along with several corporate governance proposals” on March 28. FACT:Mr. Kill offered to separate the Chairman and CEO roles at the Company’s February 18 Board Meeting.Cog
Slide 12: Corporate Governance: Vacated Key Management Positions
* Corporate Governance Pell Statement “Key management positions have been vacated…and have gone unfilled or consolidated under the current CEO.” FACT: The only open key management position in the Company has been the CFO role. Korn Ferry, an executive search firm, was engaged to conduct a search. A
Slide 13: Corporate Governance: Vacated Positions and Merger Decisions
* Corporate Governance Pell Statement “Key management positions have been vacated…and have gone unfilled or consolidated under the current CEO.” FACT: Other than the company’s CFO transition, these “vacated” positions have been decisions made by the management team in order to position the business
Slide 14: Corporate Governance: Senior Team and Director Departures
* Corporate Governance Pell Statement“Why are so many senior team members/directors abandoning CGNT?” FACT: Only one senior team member has “abandoned” CGNT, and Mr. Pell’s past comments indicate that this departure was not an issue from his perspective. As for the director departures, we believe Mr
Slide 15: Corporate Governance: Mr. Kill's Multiple Roles
* Corporate Governance Pell Statement“Why have UPI Directors allowed Mr. Kill to act in so many capacities?” FACT: Mr. Kill was appointed by the Cogentix Medical Board of Directors (including Mr. Pell) as President, CEO and Chairman at the time of the merger. Mr. Kill only assumed the roles of Princ
Slide 16: Corporate Governance: Altamont Capital Relationship
* Corporate Governance Pell Statement“Mr. Kill…is separately an Operating Partner with Altamont Capital Partners.” FACT: Mr. Kill was an Operating Partner with Altamont Capital Partners prior to becoming the CEO of Uroplasty. When he was appointed CEO of Uroplasty, his relationship with Altamont Cap
Slide 17: Corporate Governance: Withdrawal of Revenue Guidance
* Corporate Governance Pell Statement“What changed since merger announcement to warrant withdrawal of revenue guidance?” FACT: Management has been transparent about the Q1 2016 launch of Medtronic’s NURO to compete with Urgent PC. On the advice of investor relations professionals, management stated
Slide 18: Strategy: Credible Strategy Against NURO
* Strategy Pell Statement “CGNT has failed to present a credible strategy to compete with threat posed by Medtronic’s NURO system.” FACT: Management has outlined the same consistent strategy at each and every Board Meeting since the merger. At the most recent in-person Board Meeting held on February
Slide 19: Strategy: VSCI Merger and Diversification
* Strategy Pell Statement“CGNT has failed to present a credible strategy to compete with threat posed by Medtronic’s NURO system.” FACT: The merger with VSCI was completed to diversify UPI’s product portfolio in advance of the impending launch of Medtronic’s NURO system. The addition of VSCI technol
Slide 20: Strategy: NURO as Existential Threat
* Strategy Pell Statement“Medtronic’s NURO system poses an existential threat as it competes directly with CGNT’s Urgent PC product.” FACT: The overactive bladder is a large and underserved market, and third-line treatments such as Urgent PC have penetrated less than 5% of the addressable market. We
Slide 21: Strategy: Product Pipeline
* Strategy Pell Statement “What does the product pipeline look like?” FACT: The Company has initiated a project to redesign and upgrade our Digital Processing Unit, which is used to display, store and analyze still and video images generated by our video endoscopes and cameras.This $1.4 million inve
Slide 22: Strategy: No New Product Pipeline Claim
* Strategy Pell Statement “CGNT has no new product pipeline that would help offset the potential impact of NURO on UPC sales.” FACT: Cogentix Medical has additional R&D projects in the pipeline. Our ability to execute on multiple opportunities simultaneously is limited by our current cash position.
Slide 23: Strategy: Strategic Alliances and Acquisitions
* Strategy Pell Statement “Why hasn’t CGNT announced any new strategic alliance/acquisition to bolster its portfolio?” FACT: As a member of the Board, Mr. Pell is well aware of the numerous opportunities the company has reviewed in the past year as well as those that are currently being pursued, non
Slide 24: Strategy: Blocked Financing Opportunity
* Strategy Pell Statement “Why hasn’t CGNT announced any new strategic alliance/acquisition to bolster its portfolio?” FACT: Mr. Pell blocked an opportunity to obtain financing to expand the product portfolio by refusing to agree to reasonable terms to acknowledge the subordination of his debt to th
Slide 25: Share Price Performance: History of Destroying Value
* Share Price Performance Pell Statement “Rob Kill and former UPI directors have a history of destroying shareholder value.” FACT: Uroplasty’s share price rose 41% from the date of Mr. Kill’s appointment as CEO until the date of the merger announcement with VSCI. The share price dropped 50% after th
Slide 26: Share Price Performance: Decline Since the Merger
* Share Price Performance Pell Statement “CGNT’s share price has declined 35% since the merger….underperforming its peer median and major indices.” FACT: While we are not satisfied with the decline in our share price in the one-year period between April 1, 2015 and March 31, 2016, we have outperform
Slide 27: Compensation: Peer Group Selection
* Compensation Pell Statement“Inappropriate Compensation Peer Group” and “We question UPI Directors Choice of Peer Group.” FACT: In 2014, the Uroplasty Board of Directors engaged Frederic W. Cook & Company, a nationally recognized compensation consulting firm. Frederic W. Cook, using their professio
Slide 28: Compensation: Salary and Bonus Increase Claim
* Compensation Pell Statement “UPI Directors approved increase in Mr. Kill’s salary and bonus in 2015.” FACT: Mr. Kill’s cash compensation was set in 2014 and, pursuant to Mr. Kill’s request, has not increased since that date. Mr. Kill’s target bonus opportunity also has not changed since the UPI Di
Slide 29: Compensation: High CEO Pay Despite Deteriorating Performance
* Compensation Pell Statement“High CEO Comp Despite Deteriorating Performance” FACT: In Fiscal Year 2014, the Company generated $24.6 million in revenue with a cash operating loss of $3.5 million. In Fiscal Year 2016, the Company is expecting to generate greater than $50 million in revenue and is ex
Slide 30: Compensation: Pay Aligned With Performance and Say on Pay
* Compensation Pell Statement “UPI Directors Have a History of Not Aligning Pay with Performance” in regards to the ISS “Say on Pay” Recommendation FACT: Mr. Pell statements about the 2014 Uroplasty “Say on Pay” Proposal are misleading. The negative recommendation of ISS was not based on the level o
Slide 31: Compensation: Mr. Kill's Pay Is Excessive
* Compensation Pell Statement “Mr. Kill’s Pay Is Excessive” FACT: The peer group data presented in Mr. Pell’s chart (Slide 17) to support this statement is inaccurate. The cash compensation of 8 out of 12 CEO comps for Mr. Kill was understated in Mr. Pell’s chart by an average of $330,000 per CEO. C
Slide 32: Compensation (Continued): Mr. Kill's Pay Is Excessive
* Compensation Pell Statement (Continued)“Mr. Kill’s Pay Is Excessive” FACTMr. Pell indicates that Mr. Kill has received total cumulative compensation of $5.0 million since being named CEO, which is misleading to investors. Mr. Kill’s compensation is not paid entirely in cash as Mr. Pell would like
Slide 33: Cogentix Medical May 2016
Cogentix Medical NASDAQ: CGNT May 2016
Slide 34: Non-GAAP Financial Measures
* Non-GAAP Financial Measures The tables set forth below titled “Pro forma Combined Revenue (Unaudited)” provides the non-GAAP, pro forma combined revenue as if Vision-Sciences, Inc. and Uroplasty, Inc. had merged as of the earliest reported date and is the sum of the historical results of each pred
Slide 35: Pro Forma Combined Revenue, Third Quarter
COGENTIX MEDICAL, INC. AND SUBSIDIARIES. PRO FORMA COMBINED REVENUE (UNAUDITED) (NON-GAAP) ‘THIRD QUARTER ENDED December 31, (dollars in thousands) Market/Product 2015 2014 SChange % Change Urology 3511 S$ 2,746 165 21.9% Airway Management 1,068 1,107 G9), (3.5%) Industrial 1401 1,067 344 32.2% Form
Slide 36: Pro Forma Combined Statement of Operations, Third Quarter
COGENTIX MEDICAL, INC. AND SUBSIDIARIES. PRO FORMA COMBINED STATEMENT OF OPERATIONS (UNAUDITED) (NON-GAAP) ‘THIRD QUARTER ENDED December 31, (dollars in thousands) 2015, 2014 SChange _% Change Revenue S 13,688 S$ 11587 S$ 2,048 17.7% Gross profit 8,725 7,793 932 12.0% 64.0% 673% Operating costs 8,76
Slide 37: Pro Forma Combined Revenue, Nine Months
(dollars in thousands) ‘Market/Product Urology ‘Airway Management Industrial Former VSCI Revenue UPC MPQ Other Former UPI Revenue ‘Combined Revenue Cogentix Medical COGENTIX MEDICAL, INC. AND SUBSIDIARIES. PRO FORMA COMBINED REVENUE (UNAUDITED) (NON-GAAP) NINE MONTHS ENDED December 31, 2015 2014 S C
Slide 38: Pro Forma Combined Statement of Operations, Nine Months
COGENTIX MEDICAL, INC. AND SUBSIDIARIES. PRO FORMA COMBINED STATEMENT OF OPERATIONS (UNAUDITED) (NON-GAAP) NINE MONTHS ENDED December 31, (dollars in thousands) 2015, 2014 SChange _% Change Revenue S 36,622 S$ 32,288 S$ 4,334 13.4% Gross profit 24,103 21,493 2.610 12.1% 65.8% 66.6% Operating costs 2
Slide 39: Cogentix Medical May 2016
Cogentix Medical NASDAQ: CGNT May 2016